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Special Collection
TNBC in 2019: promising signals for the 
treatment of a formidable disease
Introduction
Triple negative breast cancer (TNBC) is defined 
based on the lack of the expression of the estro-
gen (ERD) and progesterone (PR) receptors, as 
well as the absence of HER2 amplification. As 
this is a diagnosis of exclusion, TNBC is a highly 
heterogeneous subgroup of breast cancer with 
poor outcome. While numerous studies have 
aimed to further stratify TNBC in order to tailor 
treatment (reviewed in Bianchini and col-
leagues)1, to date these have not resulted in a 
change in standard of care (SoC); most patients 
receive DNA-damaging chemotherapy ± taxanes 
in the adjuvant and, more recently, the neo-
adjuvant setting.2,3 While some patients respond 
very well to this treatment regimen, there is still 
a significant proportion of patients who receive 
little clinical benefit, relapse and die from their 
disease in a short period of time.4 Therefore, 
there is a significant unmet clinical need to iden-
tify biomarkers that allow TNBC to be stratified 
based on knowledge of the underlying biology 
and for treatment options to be tailored 
accordingly.
Pin1 plays a key role in the response to 
treatment and clinical outcome in triple 
negative breast cancer
Catherine Knowlson, Paula Haddock, Victoria Bingham, Stephen McQuaid, Paul B. Mullan 
and Niamh E. Buckley
Abstract
Background: Triple negative breast cancer (TNBC) is the subset of breast cancer associated 
with the poorest outcome, and currently lacks targeted treatments. Standard of care (SoC) 
chemotherapy often consists of DNA damaging chemotherapies ± taxanes, with a range of 
responses observed. However, we currently lack biomarkers to predict this response and lack 
alternate treatment options.
Methods: Pin1 expression was modulated in vitro and proliferation and treatment response 
was studied. Pin1 expression was analysed in patient samples and correlated with clinical 
outcome.
Results: In this study, we have shown that the prolyl isomerase, Pin1, which is highly 
expressed in TNBC, plays a key role in pathogenesis of the disease. Knockdown of Pin1 in 
TNBC resulted in cell death while the opposite is seen in normal cells. We revealed for the 
first time that loss of Pin1 leads to increased sensitivity to Taxol but only in the absence of 
functional BRCA1. Conversely, loss of Pin1 results in decreased sensitivity to DNA-damaging 
agents independent of BRCA1 status. Analysis of Pin1 gene or IHC-based expression in over 
200 TNBC patient samples revealed a novel role for Pin1 as a TNBC-specific biomarker, with 
high expression associated with improved outcome in the context of SoC chemotherapy. 
Preliminary data indicated this may be extended to other treatment options (e.g. Cisplatin/
Parp Inhibitors) that are gaining traction for the treatment of TNBC.
Conclusions: This study highlights the important role played by Pin1 in TNBC and highlights 
the context-dependent functions in modulating cell growth and response to treatment.
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We and others have shown that the prolyl isomer-
ase, Pin1, is transcriptionally repressed by BRCA1.5,6 
Furthermore, we have shown that high Pin1 lev-
els, as observed in the absence of functional 
BRCA1, results in increased activity of the Src 
family kinase, Lyn.5 This leads to increased 
migration and invasion, key features of aggressive 
breast cancer. Given the strong link between 
BRCA1 dysfunction (BRCAness) and TNBC,7 
as well as association of Pin1 with poor prognos-
tic factors such as high grade,8 we thought it per-
tinent to investigate the role of Pin1 in TNBC 
and the potential therapeutic implications.
Materials and methods
Cell lines
All cell lines have been described before,9 with the 
exception of the HCC3153 cells which were 
obtained from Adi Gazdar (UT Southwestern, 
Dallas, TX, USA). Cell lines were characterized 
by isoenzyme/cytochrome c oxidase I (COI) assay 
and short tandem repeat (STR) analysis by 
ATCC.
Growth assays and dose response curves
Cells were pretreated with short interfering RNA 
(siRNA) for 24 h before reseeding at an optimized 
cell density. For growth assays, cells were stained 
with crystal violet and quantified at an absorb-
ance of 570 nm following reabsorption with 
sodium citrate. For dose response curves, cells 
were treated with (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium (MTT; Sigma, St. 
Louis, MO, USA) for 3–4 h, 72 h post drug treat-
ment. Crystals were reabsorbed with DMSO and 
quantified at an absorbance of 570 nm. All chem-
otherapies were obtained from the Belfast City 
Hospital Pharmacy. UMI-77 was purchased from 
Cayman Chemicals (Ann Arbor, MI, USA) and 
Olaparib was purchased from Axon MedChem 
(Groningen, The Netherlands).
Short interfering RNA
Transfections were done using RNAiMax reagent 
(Invitrogen, UK), as outlined in the manufactur-
er’s instructions. siRNA oligonucleotides were 
obtained from Eurofins and used at a final con-
centration of 10 nM. Scr: AAGCAGCACGACT 
TCTTCAAG and Pin1: CTGGCCTCACAGTT 
CAGCG and GCTCAGGCCGAGTGTACTA
Western blot analysis
Protein lysates were extracted in EDTA Lysis 
Buffer (ELB) (0.25 M NaCl, 0.1% IEPGAL, 
0.25 M Hepes, 5 mM EDTA, 0.5 mM DTT), 
separated on a SDS PAGE gel, transferred to a 
PVDF membrane followed by immunoblotting. 
Antibodies were purchased from SantaCruz 
(Pin1- sc15340, GAPDH - sc32233, Mcl-1 - 
sc12765, CtIP - sc271339, BRCA1 -sc6954 and 
Cleaved Caspase 3 - sc56055) and Cell Signalling 
[Chk2–2662 and 2197 (T68)] (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA).
RNA extraction, reverse transcription and  
real-time quantitative PCR
RNA was extracted using RNA STAT60 Total 
RNA extraction reagent (Tel-Test Inc, Friends-
wood, TX, USA), reverse transcribed using the 
Transcriptor First Strand cDNA Synthesis kit 
(Roche, Welwyn Garden City, UK) and real-time 
quantitative PCR (RqPCR) analysis performed 
on the LC96 (Roche) using Sybr Green (Roche) 
according to the manufacturer’s instructions. 
Primers used were; Pin1: F GAAGATCACCCGG 
ACCAAG, R AAGTCCTCCTCTCCCGACTT; 
HPRT1: F TGACCTTGATTTATTTTGCA 
TACC, R CGAGCAAGACGTTCAGTCCT; 
ACTB: F TCCTCCCTGGAGAAGAGCTA, R 
CGTGGATGCCACAGGACT
Pin1 immunohistochemistry
Tissue microarrays (TMAs) were obtained from 
the Northern Ireland Biobank as previously 
described,10 and the Breast Cancer Now Tissue 
Bank with ethical approval (NIB12-0043 and 
TR-00055, respectively). Both biobanks have 
ethical approval to use deidentified tissue samples 
from the NHS tissue pathology archives with 
matched deidentified data. In accordance with 
the Human Tissue Act, consent is not required 
for use of archived, deidentified tissue in research 
studies with ethical approval.
The Breast Cancer Now Tissue Bank TMA was 
constructed from formalin-fixed paraffin-embed-
ded (FFPE) primary block by the biobank, with 
each tumour sample represented by three inde-
pendent 1 mm diameter cores. These were 
obtained from 115 TNBC patients undergoing 
surgery and SoC treatment between 1988 and 
2014. All patients were Grade 3 with a median 
age of 45 (Range 28–96) and median follow-up of 
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8 years. Both TMA cohorts were powered to 
detect a minimum Hazard ratio of 2 with 80% 
power (alpha = 0.05) based on an event rate of 
~30%, which is normally observed in TNBC.
Immunohistochemistry (IHC) was performed in 
a hybrid laboratory (Northern Ireland Molecular 
Pathology Laboratory) that has UK Clinical 
Pathology Accreditation, and the infrastructure 
to process both clinical patient samples and 
research materials. Sections were cut from the 
TMA blocks for Hematoxylin and eosin (H&E) 
staining and IHC. The initial section was used for 
H&E staining to assess TMA quality and appro-
priate tumour content for subsequent IHC locali-
zation and analysis. Sections for IHC were cut at 
4 µm on a rotary microtome, dried at 37°C over-
night, and then used for IHC, performed on an 
automated immunostainer (Leica Bond-Max, 
Milton Keynes, UK). Repeat ER, PR and HER2 
IHC were performed to confirm the triple nega-
tive status all samples in the TMA as previously 
described.11 The Pin1 antibody was validated in 
house using positive and negative whole-face 
breast cancer sections identified through gene 
expression before the TMAs were stained. 
Antigen-binding sites were detected with a poly-
mer-based detection system (Bond, Newcastle 
Upon Tyne, UK, Cat. No. DS 9800). All sec-
tions were visualized with diaminobenzidine, 
counterstained with haematoxylin, and mounted 
in DPX. Biomarker conditions were as follows. 
Pin1 (sc-46660) was used at a 1:200 with epitope 
retrieval solution 1 pretreatment for 20 mins.
Only cores with identifiable tumour as confirmed 
by pathology assessment of H&E slides were used 
in IHC analysis. All IHC was scored indepen-
dently by at least two experienced immunohisto-
chemists blinded to patient clinicopathological 
and outcome data.
Survival analysis and statistics
All survival analysis (Relapse and Overall) and 
statistical analysis was carried out using GraphPad 
Prism (v8.2).
Results
We first investigated Pin1 expression using a pub-
licly available RNASeq dataset of 77 breast can-
cer cell lines.12 Pin1 expression varied significantly 
(p = 0.0396) across breast cancer subtypes defined 
by the three gene (ER/PR/HER2) classifier, with 
the highest expression observed in TNBC (Figure 
1a(i)). Examination of TNBC in more detail 
showed a range of expression across the cell lines 
[Figure 1a(ii) and Supplementary Table S1], with 
no significant correlation observed between Pin1 
expression and the molecular subtypes of breast 
cancer defined by Lehmann and colleagues 
[Figure 1a(iii)].13 Consistent with the in silico 
findings, when Pin1 protein and mRNA expres-
sion was studied in a panel of TNBC cell lines, 
Pin1 was detected in all cell lines tested with 
highest expression in the BRCA1-low MDA-468 
cells (Figure 1b and c).14
We next wanted to understand the functional sig-
nificance of the high Pin1 expression observed in 
TNBC. In order to do this, we first knocked 
down Pin1 by siRNA in TNBC cell lines and 
measured cell growth. Pin1 siRNA resulted in a 
significant decrease in cell growth in all cell lines 
studied (Figure 2a). This was associated with an 
increase in cleaved caspase 3 (Figure 2b) indicat-
ing this is mediated by apoptotic cell death. 
Interestingly, knockdown of Pin1 in the normal 
breast cell lines, HME1 and 184A1 lead to a sig-
nificant increase in cell growth (Figure 2c and 
Supplementary Figure S1).
Next, we wanted to investigate the role of Pin1 in 
response to chemotherapy, as Pin1 has been 
linked to drug resistance and chemotherapy is 
SoC for TNBC.15 We first examined the effect of 
Pin1 knockdown on the cellular response to the 
antimicrotubule agent Taxol (Paclitaxel) using 
dose response curves. While no difference was 
observed in BRCA1-proficient cell lines (Figure 3a, 
Supplementary Figure S2a and Supplementary 
Table S2a), loss of Pin1 expression was associ-
ated with a significant increase (~10 fold) in sen-
sitivity to Taxol in the BRCA1 mutant HCC-1937 
and Sum149 cell lines (Figure 3b). In order to 
investigate this further, the isogenic MDA-468 
cell line, where wildtype BRCA1 is overexpressed 
in the BRCA1-low MDA-468 cell line, was uti-
lized.14 As we have shown previously,5 BRCA1 
expression represses the expression of Pin1 
[Supplementary Figure S2b(i)]. Consistent with 
the known role of BRCA1 in the cellular response 
to antimicrotubule agents,16,17 overexpression of 
BRCA1 results in a significant increase in sensi-
tivity to Taxol (IC50 71 nM versus 7 nM). 
Knockdown of Pin1 with two independent siRNA 
sequences also resulted in a significant increase in 
cell death and sensitivity to Taxol but only in the 
MDA468 EV BRCA1 low cell line [Figure 3c, 
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Supplementary Figure S2b(ii), 2c and Supple-
mentary Table S2b]. We hypothesized that dif-
ferential effect may be mediated by the antiapoptotic 
Bcl-2 family member, Mcl-1, which has been 
shown to play a key role in the cellular response to 
Taxol.18 Furthermore, Pin1 has been shown to 
modulate this response through stabilization of 
the Mcl-1 protein. Consistent with this, knock-
down of Pin1 resulted in loss of Mcl-1 expression 
in untreated cells and Taxol treatment resulted in 
loss of Mcl-1 protein expression in the MDA468 
BR cells. Conversely, in the absence of functional 
BRCA1, where high Pin1 levels are present, 
Mcl-1 levels remain high and are associated with 
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Figure 1. (a) RNASeq-based Pin1 expression in breast cell lines categorized by 3 gene classifier (i), TNBC cell 
line (with normal cell lines indicated in black) (ii) and Lehman TNBC subtype (iii) from the publicly available 
GSE73526. Variance was tested by one-way ANOVA (p = 0.0396). (b) Western blot of a panel of TNBC cell lines 
probed with Pin1 and GAPDH as a housekeeper. (c) Real-time PCR analysis of Pin1 mRNA expression in the 
same panel of TNBC cell lines as (b). The housekeeper gene E-tubulin was used as a loading control.
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PCR, polymerase chain reaction; TNBC, triple negative breast cancer.
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(a)
(b)
(c)
Figure 2. (a) Growth assays of (i) MDA157, (ii) BT549, (iii) MDA231, (iv) SUM149, (v) HCC1937 and (vi) MDA468 
cells pretreated with either Pin1 or Scr siRNA as a control. After 5–7 days, cells were stained with crystal 
violet, reabsorbed and quantified at A570 nm. Cell growth was normalized to Scr control (p = 0.0126, 0.0001, 
0.0009, 0.0032, 0.0052 and 0.0138 respectively). (b) Western blot of the same cells as (a) treated with either 
Pin1 or Scr siRNA for 72 h. Blots were then probed with Pin1, Caspase-3 and GAPDH as a loading control. 
(c) Growth assays of (i) HME1 and (ii) 184A1 cells pretreated with either Pin1 or Scr siRNA as a control. 
After 5–7 days, cells were stained with crystal violet, reabsorbed and quantified at A570 nm. Cell growth was 
normalized to Scr control (p ⩽ 0.0001 and 0.0271 respectively).
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; Scr, Scrambled; siRNA, short interfering RNA
Therapeutic Advances in Medical Oncology 12
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(a)
(c)
(d)
(e)
(b)
Figure 3. Dose response curve of (a) (i) MDA157, (ii) BT549, (iii) MDA231, (b) (i) SUM149 and (ii) HCC1937 cells 
pretreated with either Pin1 or Scr siRNA for 24 h before treatment with a range of concentrations of Taxol for 
72 h. Cell viability was then assessed by MTT with cell survival normalized to vehicle control (100%). (c) Dose 
response curve of the BRCA1-low MDA468 cells stably transfected with BR or EV control pretreated with either 
Pin1 or Scr siRNA for 24 h before treatment with a range of concentrations of Taxol for 72 h. Cell viability was 
then assessed by MTT with cell survival normalized to vehicle control (100%). (d) Western blot of the BRCA1-
low MDA468 cells stably transfected with BR or EV control pretreated with either Pin1 or Scr siRNA for 24 h 
before treatment with vehicle control or 1nMTaxol for 24 h. Blots were then probed with Mcl-1, Pin1 and 
GAPDH as a loading control. (e) Dose response curve of MDA468 EV cells pretreated with 1 µM of the Mcl-1 
inhibitor, UMI-77, before treatment with a range of concentrations of Taxol for 72 h. Cell viability was then 
assessed by MTT with cell survival normalized to vehicle control (100%).
BR, BRCA1; EV, empty vector; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium; Scr, Scrambled.
C Knowlson, P Haddock et al.
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resistance to treatment (Figure 3d). In order to test 
this hypothesis further, we utilized the Mcl-1 
inhibitor, UMI-77,19 and showed a ninefold 
increase in sensitivity to Taxol in the MDA468 EV 
cells line compared with that observed with Pin1 
siRNA (Figure 3e and Supplementary Table S2c).
We next wanted to investigate the role of Pin1 in 
the response to DNA-damaging chemotherapy 
utilizing an FEC-like cocktail, FEM, to mimic 
SoC (5-FU, Epirubicin and Mitomcyin C replac-
ing Cyclophosphamide, which required meta-
bolic activation in vivo). In contrast to what was 
observed in the context of Taxol, Pin1 siRNA 
resulted in a decrease in sensitivity to FEM as 
shown by dose response curve and cleaved cas-
pase 3 western blot in both BRCA1 proficient 
[Figure 4a and Supplementary Figure S3a(i)] and 
deficient cell lines [Figure 4b, Supplementary 
Figure S3a(ii) and Supplementary Table S3a]. 
Similar results were also observed with a second 
siRNA sequence (Supplementary Figure S3b and 
c). Pin1 has previously been linked to double-
strand break repair, with overexpression of Pin1 
suppressing HR though destabilization of CtIP.20 
While we were able to recapitulate the findings of 
Steger and colleagues in the U20S cell line [Figure 
4c(i)],20 increased phosphorylation of CtIP (a key 
event in DSB repair) following Pin1 siRNA and 
treatment with the DNA-damaging agent, 
Doxorubicin, was not observed in the MDA-468 
cell line despite the increase in resistance (Supple-
mentary Figure S3c and Supplementary Table 
S3b). In fact, an overall decrease in CtIP levels 
(a)
(b)
(c)
Figure 4. Dose response curves of (a) (i) MDA157, (ii) BT549, (iii) MDA231, (b) (i) SUM149 (ii) HCC1937 
and (iii) MDA468 cells pretreated with either Pin1 or Scr siRNA for 24 h before treatment with a range of 
concentrations of a cocktail of 5-FU, Epirubicin and Mitomycin C (FEM)for 72 h. Cell viability was then assessed 
by MTT with cell survival normalized to vehicle control (100%). (c) Western blot of (i) U2OS and (ii) MDA468 
cells pretreated with either Pin1 or Scr siRNA for 24 h before treatment with vehicle control or 20 µM Dox 
for 6h. Blots were then probed with CtIP, Pin1, Mcl-1 and GAPDH as a loading control. The upper CtIP band 
represents hyperphosphorylated CtIP.
DOX, doxorubicin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium; Scr, Scrambled.
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was observed [Figure 4c(ii)]. As expected, Mcl-1 
was downregulated by treatment with doxoru-
bicin as anthracyclines are known to be global 
repressors of transcription that preferentially 
impact Mcl-1, given the short half-life of the 
mRNA.21 This was not modulated by Pin1 
expression [Figure 2c(ii)], indicating that there 
may be multiple mechanisms underpinning the 
modulation of DNA repair by Pin1.
Given the role of Pin1 in multiple cancer-associated 
phenotypes, we next wanted to investigate whether 
Pin1 expression could be used as a biomarker to 
predict outcome in patients with TNBC. Previous 
published data showed that Pin1 was associated 
with high grade and poor prognosis breast can-
cer.8,22,23 This was recapitulated in the analysis of a 
largely untreated TNBC cohort,24 showing that 
high Pin1 mRNA was significantly associated with 
decreased relapse-free survival [hazard ratio (HR) 
1.7; 95% confidence interval (CI) 1.26–2.3; 
p = 0.0005] [Figure 5A(i) and Supplementary 
Table S4A]. However, given the role of Pin1 in 
DNA repair, we hypothesized that Pin1 may play 
an alternative role as a predictive biomarker to 
DNA-damaging chemotherapy. Indeed, analysis of 
an FEC-treated TNBC cohort showed that high 
Pin1 mRNA expression was associated with 
improved relapse free survival,9 although this did 
not quite reach significance (p = 0.0747) [Figure 
5A(ii) and Supplementary Table S4A]. To explore 
this further, we carried out Pin1 IHC on two inde-
pendent TNBC cohorts, both treated with SoC 
chemotherapy. A range of expression of Pin1 was 
observed scored as absent (0), low (1), intermedi-
ate (2), high (3) and extremely high (4) expression 
(Figure 5b). When present, Pin1 was expressed in 
both the cytoplasm and the nucleus, consistent with 
its known patterns of localization.25 Pin1 expression 
was then correlated with relapse-free and overall 
survival. Based on preliminary investigations, 
patients were stratified based on low (Score 0 and 1) 
and high (Score 2–4) Pin1 expression. Consistent 
with the gene expression data, high Pin1 was sig-
nificantly associated with improved relapse-free 
and overall survival in both the Northern Ireland 
and Breast Cancer Now Biobank cohorts of 
patients treated with SoC DNA Damaging chemo-
therapy (Figure 5c and d and Supplementary Table 
S4B). This appeared to be TNBC specific, as analy-
sis of a larger cohort of FEC-treated breast cancer 
cases representing all molecular subgroups of breast 
cancer showed no differences on survival based on 
Pin1 expression in Luminal (ER+) or HER2+ dis-
ease (Figure 5E and Supplementary Table S4C).11
Discussion
In this study we have shown that Pin1 is highly 
expressed in a subset of TNBC and plays an 
important role in pathogenesis and response to 
treatment. We show that knockdown of Pin1 in 
TNBC cell lines results in cell death, while 
increased proliferation is observed in normal 
breast cell lines. Pin1 functions as a differential 
modulator of chemotherapy response with both 
BRCA1-depdendent and independent roles. In 
the context of the antimicrotubule agent Taxol, 
knockdown of Pin1 results in increased sensitivity 
but only in the absence of functional BRCA1. We 
suggest this is mediated through Pin1-dependent 
stabilization of Mcl-1. Conversely, knockdown of 
Pin1 results in decreased sensitivity to DNA-
damaging chemotherapy. This is observed in both 
BRCA1 proficient and deficient cell lines. This 
translates to a potential role for Pin1 as a biomarker 
to predict response to DNA damaging chemother-
apy, which is SoC for TNBC (Figure 6).
Pin1 has been shown to be essential for breast 
development and plays an oncogenic role in a 
number of cancer types including breast can-
cer.15,26 Pin1 functions as a prolyl isomerase, cat-
alysing the cis-trans isomerization of proline 
residues found within pSer/Thr-Pro motifs. This 
Pin1-dependent isomerization regulates the con-
formation, and thus the function, of many key 
proteins, which impacts on many cellular path-
ways implicated in cancer, including ER-D, NFNB, 
Stat3, E-catenin, CyclinD1, AKT and Notch.27 
This highlights the potential of Pin1 as a target for 
therapy. This is further supported by the differen-
tial effect of loss of Pin1 expression in cancer 
 versus normal cells observed in our study, indicat-
ing cancer specificity. However, the increase in 
cell proliferation observed in normal cells also 
supports the potential role of Pin1 as a ‘condi-
tional tumour suppressor’ as loss of Pin1 is asso-
ciated with increased expression of cell cycle 
proteins (e.g. Cyclin E and D) and oncogenes 
(e.g. MYC) in specific genetic backgrounds.28 
Together with our result, this highlights the con-
tinuing need to understand the function of Pin1 
in health and disease.
While a number of previous studies have shown 
that inhibition of Pin1 can sensitize cells to vari-
ous chemotherapies,29–32 this is the first time that 
Pin1 has been shown to differentially modulate 
the response to Taxanes and DNA-damaging 
chemotherapy in a BRCA1 dependent and inde-
pendent manner, respectively. It is important to 
C Knowlson, P Haddock et al.
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Figure 5. (a) Kaplan–Meier curve of RFS in two TNBC datasets representing majority untreated GSE31519 
(i) and FEC-treated patients (ii)9 stratified based on high (above median) or low (below median) Pin1 gene 
expression. (b) Representative images at ×10 magnification (×40 for inset) demonstrating the scoring system 
from 0 to 4 IHC-assessed Pin1 expression. Kaplan–Meier curve of RFS (i) or OS (ii) in the (c) Northern Ireland 
Biobank or (d) BCN Biobank TNBC TMA cohorts stratified based on low (0 and 1) or high (2–4) IHC-assessed 
Pin1 expression. (e) Kaplan–Meier curve of RFS in Luminal (ER+/HER2–) and HER2+ (ER–/HER2+) patients 
from the NIB Breast 300 cohort stratified based on low (0 and 1) or high (2–4) IHC-assessed Pin1 expression. All 
HRs, 95% CIs and p values are reported in Supplementary Table S4.
BCN, Breast Cancer Now; CI, confidence interval; FEC, 5-FU, Epirubicin and Cyclophosphamide; HR, hazard ratio; IHC, 
immunohistochemistry; NIB, Northern Ireland Biobank; OS, overall survival; RFS, relapse-free survival; TMA, tissue 
microarray; TNBC, triple negative breast cancer.
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note that while Taxanes primarily function 
through inhibiting mitosis, DNA damage may 
also be caused as a consequence of mitotic catas-
trophe. Therefore, these differential effects may 
not be simply attributed to the primary mecha-
nism of action of these drugs but may also be 
influenced by differential Pin1 isomerization of 
proteins involved in drug metabolism, export or 
DNA damage specific to each drug type.
Our results support the findings of Ding and col-
leagues, who also demonstrated that Mcl-1 plays a 
crucial role downstream of Pin1 in resistance to 
Taxol.32 However, the BRCA1-dependent pheno-
type was not described. This indicates that this 
may be TNBC specific as the cells used in the previ-
ous study were either ER+ (MCF-7) or since shown 
to orginate from melanoma (MDA-MB-435).33 
This supports the tissue-specific role of BRCA1 as 
recently highlighted by Jonsson and colleagues.34 
Our results indicate a novel therapeutic strategy to 
resensitize BRCA1 mutant/dysfunction TNBC 
tumours to Taxol using either direct inhibitors of 
Mcl-1 or potentially indirect regulators such as 
Sorafenib as suggested by Ding and colleagues.32
In contrast, the CtIP-dependent mechanism 
underpinning the BRCA1-independent role of 
Pin1 in conferring sensitivity to DNA damaging 
agents reported by Steger and colleagues could not 
be recapitulated in our breast cell lines.20 This fur-
ther highlights the context specific role of Pin1, 
whereby it differentially modulates the response to 
different cellular stresses. This is supported by the 
recent publication from the Morris laboratory 
demonstrating that, in the context of replication 
stress, Pin1 enhances the interaction between 
BRCA1-BARD1 and RAD51, increasing the pres-
ence of RAD51 at stalled replication forks and 
therefore promoting fork protection.35 Our findings 
also highlight the fact that Pin1 may modulate the 
same response through different mechanisms in 
different cancer types. Unravelling the exact mech-
anism by which Pin1 regulates response to DNA 
damaging agents was beyond the scope of the cur-
rent project, but through preliminary analysis of a 
phosphokinase array used to identify key pathways 
regulated by Pin1,5 we have identified and vali-
dated the DNA repair protein CHK2 as a novel 
Pin1 target gene (Supplementary Figure S4A). 
Knockdown of Pin1 results in loss of phosphoryla-
tion of tyrosine 68, a key site in the activation of the 
kinase, indicating this may be a mechanism of 
resistance that warrants further investigation.
Regardless of the mechanism by which Pin1 regu-
lates response to DNA-damaging chemotherapy, 
this study highlights the novel potential role of Pin1 
as a biomarker to identify women likely to receive 
clinical benefit from current SoC chemotherapy 
regimens such as FEC. Furthermore, preliminary 
analysis of cell line and patient data indicates this 
may be extended to Cisplatin and Parp inhibitors, 
which are key treatment options emerging for the 
management of TNBC.4 Using publicly available 
data, we have shown that Pin1 gene expression 
negatively correlates with IC50 concentrations of 
Cisplatin (Supplementary Figure S4B) and the 
Parp inhibitor, Rucaparib (Supplementary Figure 
S4C), in TNBC cell lines but not breast cancer cell 
Figure 6. Schematic summarizing the role of Pin1 in modulating response to chemotherapy in TNBC.
FEC, 5-FU, Epirubicin and Cyclophosphamide; mut, mutated; TNBC, triple negative breast cancer; WT, wild type.
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lines as a whole (Supplementary Table S5A).36 We 
have recapitulated this in vitro, demonstrating that 
knockdown of Pin1 results in decreased sensitivity 
to both agents in the MDA-MB-468 cell line 
(Supplementary Figure S3D and Supplementary 
Table S5B). Furthermore, analysis of TNBC 
patients treated with Cisplatin shows that Pin1 
expression correlates significantly (p < 0.0001) with 
treatment response quantified using the Miller-
Payne scale (Supplementary Table S4C).37 Based 
on our own results in the context of SoC, and the 
preliminary indications in the context of other 
treatment, this warrants further analysis of the 
potential role of Pin1 as a prognostic and predictive 
biomarker in additional patient cohorts.
In conclusion, this study demonstrates the onco-
genic role of Pin1 driving treatment response in 
TNBC. The ability of Pin1 to differentially mod-
ulate response to treatment emphasizes its con-
text-specific function and highlights the need for 
continued investigations into the roles of Pin1 in 
normal cell function as well as cancer. Finally, we 
highlight the potential of Pin1 as a novel bio-
marker for the stratification of TNBC patients for 
treatment in order to improve the management of 
this poor outcome cancer.
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